Cargando…

Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke

Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker elevated in cardiovascular diseases. The aim of this 3-year follow-up prospective study was to evaluate suPAR levels in patients with a first ischemic stroke in correlation with CRP, PCT, NT-proCNP and endothelin 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Różański, Dorota, Szlufik, Stanisław, Tomasiuk, Ryszard, Milanowski, Łukasz, Figura, Monika, Saramak, Kamila, Myrcha, Piotr, Koziorowski, Dariusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774014/ https://www.ncbi.nlm.nih.gov/pubmed/35053782 http://dx.doi.org/10.3390/brainsci12010039

Ejemplares similares

Mechanisms of Neurodegeneration in Various Forms of Parkinsonism—Similarities and Differences
por: Koziorowski, Dariusz, et al.
Publicado: (2021)

Proteomic Profile of Saliva in Parkinson’s Disease Patients: A Proof of Concept Study
por: Figura, Monika, et al.
Publicado: (2021)

Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson’s disease
por: Turski, Paweł, et al.
Publicado: (2022)

Glymphatic System and Mitochondrial Dysfunction as Two Crucial Players in Pathophysiology of Neurodegenerative Disorders
por: Kopeć, Kamila, et al.
Publicado: (2023)

Serum amino acid profile in patients with Parkinson’s disease
por: Figura, Monika, et al.
Publicado: (2018)

The prognostic value of concomitant assessment of NT-proCNP, C-reactive protein, procalcitonin and inflammatory cytokines in septic patients
por: Tomasiuk, Ryszard, et al.
Publicado: (2014)

Assessment of factors influencing glymphatic activity and implications for clinical medicine
por: Gędek, Adam, et al.
Publicado: (2023)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2018)

Urokinase-type Plasminogen Activator Induces Neurorepair in the Ischemic Brain
por: Merino, Paola, et al.
Publicado: (2018)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor level in individuals of advanced age
por: Wlazel, Rafal N., et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

Personalised Approach to Diagnosing and Managing Ischemic Stroke with a Plasma-Soluble Urokinase-Type Plasminogen Activator Receptor
por: Śmiłowska, Katarzyna, et al.
Publicado: (2022)

The Neuromodulatory Impact of Subthalamic Nucleus Deep Brain Stimulation on Gait and Postural Instability in Parkinson's Disease Patients: A Prospective Case Controlled Study
por: Szlufik, Stanislaw, et al.
Publicado: (2018)

The Anatomy of the Circle of Willis Is Not a Strong Enough Predictive Factor for the Prognosis of Cross-Clamping Intolerance during Carotid Endarterectomy
por: Myrcha, Piotr, et al.
Publicado: (2020)

Urokinase-type plasminogen activator promotes synaptic repair in the ischemic brain
por: Diaz, Ariel, et al.
Publicado: (2018)

Urokinase-type Plasminogen Activator Promotes Synaptic Recovery in the Ischemic Brain
por: Yepes, Manuel
Publicado: (2018)

Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
por: Wittenhagen, Per, et al.
Publicado: (2011)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
por: Erkut, Nergiz, et al.
Publicado: (2016)

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
por: Böcskei, Renáta M., et al.
Publicado: (2019)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea
por: Bocskei, Renata Marietta, et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

A Multimodal Approach to the Quantification of Kinetic Tremor in Parkinson’s Disease
por: Szumilas, Mateusz, et al.
Publicado: (2019)

Cervical dystonia and no oculomotor apraxia as new manifestation of ataxia-telangiectasia-like disorder 1 – case report and review of the literature
por: Bajek, Agnieszka, et al.
Publicado: (2023)

Multimodal Learning and Intelligent Prediction of Symptom Development in Individual Parkinson’s Patients
por: Przybyszewski, Andrzej W., et al.
Publicado: (2016)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
por: Ichihara, Noboru, et al.
Publicado: (2017)

Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity
por: Raff, Hershel, et al.
Publicado: (2020)

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease
por: Ahmed, Reem M., et al.
Publicado: (2019)

Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
por: Velissaris, Dimitrios, et al.
Publicado: (2021)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
por: El‑Patal, Mohamed Abd‑Ellatif, et al.
Publicado: (2022)

Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
por: Hindy, George, et al.
Publicado: (2022)

Machine Learning and Eye Movements Give Insights into Neurodegenerative Disease Mechanisms
por: Przybyszewski, Andrzej W., et al.
Publicado: (2023)

Soluble Urokinase Plasminogen Activator Receptor Levels in Tuberculosis Patients at High Risk for Multidrug Resistance
por: Mardining Raras, Tri Yudani, et al.
Publicado: (2012)

Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness
por: Cyrille, Nicole B., et al.
Publicado: (2016)

Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes
por: Alfano, Massimo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vmjtskf5s8pp9e8if8jdfbq30u